Knowledge Transfer Partnership Sponsored by the Department of Trade & Industry (DTI)

Posted:
4
July 2006

We are pleased to announce that we have launched a unique research project in conjunction with Queen Mary University of London.The Knowledge Transfer Partnership (KTP) sponsored by the Department of Trade and Industry (DTI), and Richmond Pharmacology Ltd is a two year project bringing together academia and commercial expertise.The project will culminate in the development of unique software tools, which will allow for the collection and linking of data from different medical measurement devices into one central repository for analysis.Dr Dilshat Djumanov PhD, a Research Associate from Queen Mary University of London, will undertake this two year research project.Dr Dilshat Djumanov Commented The Knowledge Transfer Partnership gives me the opportunity to undertake a demanding and exciting work based project, in which the results will be implemented in to a commercial environment. Working in conjunction with and having the support from Dr Peter Dabnichki Lecturer in Medical Engineering, Queen Mary University of London, and Dr Radivoj Arezina Research Director, Richmond Pharmacology, this 2 year project will offer Richmond Pharmacology expertise on data acquisition, data processing and software design to compliment and enhance the existing procedures.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more